Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized study of IONIS GHR-LRX (ISIS 766720) monotherapy in acromegaly
2020-000675-20Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cimdelirsen in acromegaly, sponsored by Ionis Pharmaceuticals. Primary endpoint: Percent change in IGF-1 from baseline to Week 27. Started Sep 2020; status: completed.
02
Drugs
cimdelirsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2020-000675-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000675-20.